Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.

Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data

Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.

3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data

Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock.  Underwriters have an option to purchase up to an additional 15% of the shares offered in the public offering.

Intellia Seeks To Raise $400M Via Equity

An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA). Here's why.

Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know

Intellia stunned the medical community with their Phase 1 interim results.

Intellia Makes History. Can It Deliver A Cure?

Ark Invest's Cathie Wood said last year that the next "FANG" stocks would likely come from the gene editing space.

Cathie Wood's Ark ETFs are surging on big gains in CRISPR gene-editing stocks following the success of first human trials

Investors may want to closely monitor the results of a phase 3 clinical trial of Merck & Co. Inc.'s ( MRK , Financial) pill designed to protect patients from Covid-19's most severe health impact. Results from the testing of molnupiravir could come as early as September, according to an article in BioPharma Dive.

Intellia Shares Soar on Positive Test Results

As a result of this news, NTLA stock is way up, and other genome editing stocks are seeing gains as well. The post Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride appeared first on InvestorPlace.

Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride

Verve Therapeutics

Find out why these stocks are climbing higher.

Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money

The company reported promising interim trial results for its CRISPR gene-editing candidate.

Why Intellia Therapeutics Stock Is Skyrocketing Today

The shares of biotechnology name Intellia Therapeutics Inc (NASDAQ:NTLA) are soaring this morning, up 48% to trade at $131.92 at last check -- earlier hitting a record high of $144.39 -- after positive data from the company's early-stage trial of its genome-editing candidate, NTLA-2001.

Biotech Blasts to Record Highs After Upbeat Trial Data

Intellia Therapeutics Inc (NASDAQ: NTLA) said on Saturday its clinical trial that used Crispr technology to treat a genetic disorder inside the human body showed positive results. The biotech company had collaborated with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on the study that used the Nobel Prize-winning technology.

Here's why Intellia Therapeutics stock gained 55% on Monday

Intellia partnered with Regeneron in 2016 to advance the CRISPR technology for in vivo therapeutic development.

Intellia Therapeutics soars 58% after its gene-editing CRISPR therapy shows success in first human trials

Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported positive interim data from an ongoing Phase 1 clinical study of the in vivo genome editing candidate NTLA-2001.

Why Intellia Therapeutics Stock Is Soaring Today

At a meeting of neurologists Saturday morning, researchers said that the first patients to get Intellia's gene-editing treatment showed improvements in their inherited liver disorder.

First In-Vivo Gene Editing Data Look Good for Intellia

Bionano Genomics

CRISPR Therapeutics

Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ. The post Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks appeared first on InvestorPlace.

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks

Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. Interim results come from the first six patients for the in vivo CRISPR/Cas9 genome editing candidate that reduced serum levels of transthyretin, a key biomarker for the disease, by 87% in patients who received a higher dose.

Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) increased by over 30% pre-market. This is why it happened.

NTLA Stock Price Increases Over 30% Pre-Market: Why It Happened

Regeneron Pharmaceuticals

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The Phase 1 study, run by Intellia as the program's development and commercialization lead, is evaluating NTLA-2001 in people living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision editing of a gene in a target tissue in humans. NTLA-2001 is designed to inactivate the TTR gene in liver cells to prevent the production of misfolded transthyretin (TTR) protein, which accumulates in tissues throughout the body and causes the debilitating and often fatal complications of ATTR amyloidosis. The interim data were presented today at the 2021 Peripheral Nerve Society (PNS) Annual Meeting and published in The New England Journal of Medicine (nejm.org/doi/full/10.1056/NEJMoa2107454.)1.

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

Blackstone Group

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Cellex Cell Professionals GmbH (“Cellex”), the parent company of GEMoaB GmbH (“GEMoaB”), a clinical-stage cell therapy company. The new company will combine GEMoaB's world-l

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

Corbus Pharmaceuticals Holdings

Gemini Therapeutics

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

3 Biotech Stocks With Big Catalysts in June

Editas Medicine

Invitae

Here are some of our experts' favorite gene editing plays for the long run.

What's the Best Way to Invest in Genetics Stocks?

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced that a late-breaking abstract featuring interim Phase 1 clinical data from NTLA-2001, the Company's lead CRISPR/Cas9 in vivo therapy in development as a single-dose, systemically administered treatment for transthyretin (ATTR) amyloidosis, has been selected for an oral presentation at the 2021 Peripheral Nerve Society (PNS) Annual Meeting, taking place this month.

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

News for Intellia Therapeutics Stock (NTLA)